We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00232479
First Posted: October 4, 2005
Last Update Posted: August 21, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Aventis Pharmaceuticals
Information provided by (Responsible Party):
Judith Hurley, University of Miami
  Purpose
Dose dense therapy has been shown to increase survival in the adjuvant setting of breast cancer. It is unknown if dose dense therapy will improve survival in tumors that express her-2. This study evaluates a neoadjuvant regimen containing carboplatin, taxotere and herceptin when used in a dose dense manner in patients with large breast cancers. The endpoint of pathologic complete response is used as a surrogate marker for survival.

Condition Intervention Phase
Breast Cancer Drug: trastuzumab, docetaxel and carboplatin in dose dense regimen Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Dose Dense Carboplatin and Taxotere With Herceptin As Primary Systemic Therapy in Breast Cancer

Resource links provided by NLM:


Further study details as provided by Judith Hurley, University of Miami:

Primary Outcome Measures:
  • Number of Patients With Pathologic Complete Response (pCR) [ Time Frame: determined at the time of surgery which is approximately 16 weeks from the beginning of treatment ]
    pCR is defined as the absence of invasive tumor from the surgical specimen of breast and axilla which is obtained after the chemotherapy regimen has been delivered.


Secondary Outcome Measures:
  • Safety and Tolerability [ Time Frame: from the first dose of chemotherapy until surgery which was approximately 16 weeks. ]
    the number of patients with grade 4 (severe) toxicities and or hospitalizations were measured to assess safety and tolerability


Enrollment: 48
Study Start Date: September 2005
Study Completion Date: June 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: arm 1
single arm study evaluating the efficacy of neoadjuvant taxotere, herceptin and carboplatin given in a dose dense fashion
Drug: trastuzumab, docetaxel and carboplatin in dose dense regimen
trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
Other Name: herceptin, taxotere and carboplatin

Detailed Description:
Dose dense therapy has been shown to increase survival in the adjuvant setting of breast cancer. It is unknown if dose dense therapy will improve survival in tumors that express her-2. This study evaluates a neoadjuvant regimen containing carboplatin, taxotere and herceptin when used in a dose dense manner in patients with large breast cancers. The endpoint of pathologic complete response is used as a surrogate marker for survival.Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HER-2 overexpressing breast cancer
  • Clinical stage 2-3B
  • Normal ejection fraction

Exclusion Criteria:

  • Metastatic disease
  • Low ejection fraction
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00232479


Locations
United States, Florida
Jackson Memorial Hospital
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
Aventis Pharmaceuticals
Investigators
Principal Investigator: Judith Hurley University of Miami
  More Information

Responsible Party: Judith Hurley, MD, University of Miami
ClinicalTrials.gov Identifier: NCT00232479     History of Changes
Other Study ID Numbers: SCCC 2004-064
First Submitted: September 30, 2005
First Posted: October 4, 2005
Results First Submitted: June 12, 2012
Results First Posted: August 21, 2012
Last Update Posted: August 21, 2012
Last Verified: July 2012

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Docetaxel
Carboplatin
Trastuzumab
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action